General
- Upadacitinib Prescribing Information
- Risankizumab Prescribing Information
- Guselkumab Prescribing Information
- ACR COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases
- ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Biosimilars
- Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
- Biosimilars: implications for rheumatoid arthritis therapy.
- The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
- Clinical trials of biosimilars should become more similar.
- Biosimilars: More Treatment Options Are on the Way
- FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Gout
- ASN Kidney Week 2023 Abstracts
- EULAR 2023 Abstract Book
- ACR Convergence 2023 Abstracts
- Alliance for Gout Awareness Resources
- Gout Patient Education & Resources
- 2016 updated EULAR evidence-based recommendations for the management of gout
- 2020 American College of Rheumatology Guideline for the Management of Gout
- What’s new on the front-line of gout pharmacotherapy?
- A glance into the future of gout
- PROTECT: Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label clinical trial
- RECIPE: Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
- MIRROR RCT: A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
- Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
- 2022 EULAR Congress Abstract Book
- Pegloticase in Combination With Methotrexate in PatientsWith Uncontrolled Gout: A Multicenter, Open-label Study(MIRROR)
- Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients
- Treat to target in gout
- Pegloticase Prescribing Information
- Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
- Gout Patient fact Sheet
- Moving the Needle: Improving the Care of the Gout Patient
IgG4-related disease (IgG4-RD)
- International Consensus Statement on the Pathology of IgG4-Related Disease
- International Consensus Guidance Statement of the Management and Treatment of IgG4-Related Disease
- 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
- (ACR) Information on IgG4-Related Disease: What they are, Getting Diagnosed, Treatment Options, and More
- MITIGATE – Phase 3 Clinical Trial: Efficacy and Safety of Inebilizumab in IgG4-Related Disease
Immune-mediated adverse reactions
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline
- The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
- Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
- Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Psoriatic Arthritis
- Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
- Psoriatic Arthritis – Disease Primer
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
- JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
- Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
- Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
- Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Spondyloarthritis
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
- JAK1 selective inhibitors for the treatment of spondyloarthropathies
- Axial spondyloarthritis: new advances in diagnosis and management
- TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
- From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
- Recognizing Axial Spondyloarthritis: A Guide for Primary Care
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
- JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
- Pain in Axial Spondyloarthritis: More to It Than Just Inflammation
- Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities
- Spondylitis Association of America: Resources and Support
- Spondyloarthritis Patient Fact Sheet
- What Is Axial Spondyloarthritis (AxSpA)?
- Recommendations for the Treatment of Ankylosing Spondylitis
- 2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
- Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Juvenile Idiopathic Arthritis (JIA)
Lupus
- Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
- Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
- Update on lupus epidemiology: advancing health disparities research through the study of minority populations
- Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
- Lupus Foundation of American Caregiver Toolkit
- Patient Fact Sheet: Lupus
- Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
- Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
- Phase 3 AURORA study of voclosporin versus standard of care in lupus nephritis
- Belimumab prescribing information
- Voclosporin prescribing information
Rheumatoid Arthritis (RA)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- RA and Vaccinations
- RA Treat-to-Target Recommendations
- The Purple Book for Biosimilars
- RA Overview (for Patients)
- RA Treatment (for Patients)
- FDA Information on Biosimilars (for Patients)
- RA Overview (for Patients)
- RA Treatment (for Patients)
Systemic Sclerosis
- Understanding Scleroderma: National Scleroderma Foundation Patient Education
- 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
- Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Vasculitis
ANCA-Associated Vasculitis
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
- ANCA-Associated Vasculitis
- EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
- Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
- Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
- Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
- Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
- NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
- American College of Rheumatology Churg-Strauss Syndrome Classification Criteria
- National Organization for Rare Disorders: Churg Strauss Syndrome
